1. N17 Frequency of infliximab-induced skin lesions and their impact on quality of life in inflammatory bowel disease patients treated with infliximab. (25th January 2019) Authors: Bobnar Sekulic, C; Polanc, T; Koren, U; Kurent, T; Smrekar, N; Hanžel, J; Drobne, D; Novak, G Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP19 Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey. (30th January 2023) Authors: Fidalgo, C; Walsh, A; Adamina, M; Barreiro-Acosta, M; Burisch, J; Drobne, D; Faiz, O; Ferrante, M; Godny, L; Iacucci, M; Jäghult, S; Restellini, S; Rosini, F; Shouval, D; Yanai, H; Fiorino, G Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P180 Association between serum and tissue protein profiles in patients with active inflammatory bowel disease: the ASCERTAIN study. (15th January 2020) Authors: Stevens, T; Wildenberg, M; Koželj, M; Novak, G; Gecse, K; Duijvestein, M; Löwenberg, M; Drobne, D; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P252 Solid organ transplant (with the exception of liver) in patients with inflammatory bowel disease: An ECCO CONFER Multicentre Case Series. (30th January 2023) Authors: Ribaldone, D G; Vieujean, S; Julsgaard, M; Zingone, F; Savarino, E; Cañete, F; Aratari, A; Imperatore, N; Ramos, L; Plaza, R; Pugliese, D; Barberio, B; Drobne, D; Chaparro, M Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P384 Postoperative Endoscopic Recurrence In Patients With Crohn's Disease After "Curative" Ileocecal Resection on Prophylaxis Treatment With Either Anti-TNFs, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study. (21st January 2022) Authors: Yanai, H; Amir Barak, H; Kagramanova, A; Knyazev, O; Sabino, J; Haenen, S; Mantzaris, G J; Mountaki, K; Pugliese, D; Armuzzi, A; Furfaro, F; Fiorino, G; Drobne, D; Kurent, T; Yassin, S; Maharshak, N; Castiglione, F; Nardone, O M; de Sire, R; Farkas, K Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i384 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis. (25th January 2019) Authors: Kantasiripitak, W; Dreesen, E; Detrez, I; Stefanović, S; Drobne, D; Vermeire, S; Ferrante, M; Gils, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P674 Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohort. (30th January 2023) Authors: Verstockt ., B; Vieujean, S; Truyens, M; Julsgaard, M; Pugliese, D; Aslan, D; Prokopic, M; Lim, S; Viganò, C; Festa, S; Ramos, L; Garciá, M J; Plaza, R; Noviello, D; Savarino, E; Drobne, D; Imperatore, N; Ribaldone, D G; Van Dongen, J; Teich, N Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i805 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P686 Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study. (25th January 2019) Authors: Kurent, T; Koren, U; Hanzel, J; Kozelj, M; Novak, G; Smrekar, N; Stabuc, B; Kecelj, N; Drobne, D Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S463 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P702 Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease. (30th January 2023) Authors: Pintar, S; Hanžel, J; Smrekar, N; Koželj, M; Drobne, D; Kurent, T; Štabuc, B; Novak, G Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P720 Drug survival of first-line biologics in inflammatory bowel disease: large single-centre experience from UR-CARE. (30th January 2023) Authors: Hanzel, J; Supovec, E; Smrekar, N; Koželj, M; Kurent, T; Štabuc, B; Novak, G; Drobne, D Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i850 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗